ORIC Pharmaceuticals Presents Prostate Cancer Data at AACR

Preclinical findings support potential of rinzimetostat across prostate cancer and emerging resistance settings

Apr. 17, 2026 at 10:04pm by

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image revealing the intricate internal structures of a human prostate gland, conceptually illustrating the potential of new targeted therapies to disrupt the complex mechanisms of prostate cancer.Preclinical research on a novel PRC2 inhibitor suggests new ways to target the complex biology of prostate cancer and overcome treatment resistance.San Francisco Today

ORIC Pharmaceuticals, a clinical-stage oncology company, presented preclinical data at the 2026 American Association for Cancer Research (AACR) Annual Meeting that supports the potential of its investigational drug rinzimetostat across prostate cancer and in emerging resistance settings.

Why it matters

The data highlights the therapeutic potential of PRC2 inhibition, which could help address tumor adaptability and sustain the benefits of androgen-receptor targeted therapies in prostate cancer, an area of high unmet need.

The details

The preclinical findings showed that rinzimetostat, ORIC's PRC2 inhibitor, demonstrated anti-tumor activity in prostate cancer models, including those resistant to standard-of-care treatments. The data suggests PRC2 inhibition could reduce tumor adaptability and prolong the efficacy of androgen-receptor targeted therapies.

  • The data was presented at the 2026 AACR Annual Meeting on April 17, 2026.

The players

ORIC Pharmaceuticals, Inc.

A clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance.

Got photos? Submit your photos here. ›

The takeaway

The preclinical data on rinzimetostat highlights a promising new approach to treating prostate cancer by targeting PRC2, which could help overcome resistance to current therapies and improve outcomes for patients.